Multicare Pharma and KalVista Close Alliance to Introduce Oral Treatment for Rare Disease in Colombia
The alliance contemplates Multicare assuming regulatory registration, importation, and distribution. Photo: Courtesy.
TL;DR
- Multicare Pharma and KalVista Pharmaceuticals have formed an alliance to launch an oral treatment for hereditary angioedema (AEH) in Latin America.
- The agreement includes regulatory registration, importation, and distribution in Brazil, Argentina, Colombia, and Mexico.
- This treatment is the first oral on-demand therapy for acute AEH attacks, targeting patients over 12 years old.
- Multicare Pharma, a Brazilian company with 41 years of experience, sees this as a milestone in managing rare diseases.
- The company has invested US$10 million in its Colombian operations and aims to expand its portfolio of advanced therapies.